68 related articles for article (PubMed ID: 38642459)
1. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
[TBL] [Abstract][Full Text] [Related]
2. A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group.
Crawford ED; Garnick MB; Eckel RH; Miner MM; Freedland SJ; Pachynski RK; Wassersug RJ; Rosenberg MT; Walker LM; Fairman C; Curley T; Crosby M; Lin PH; Hafron JM
Urol Pract; 2024 Jan; 11(1):18-29. PubMed ID: 37917591
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
4. Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways.
Crawford DE; Albala D; Garnick MB; Hahn AW; Maroni P; McKay RR; Miner M; Orio Ⅲ P; Pandit K; Sellinger S; Yu EY; Eckel RH
Can J Urol; 2024 Apr; 31(2):11820-11825. PubMed ID: 38642459
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
6. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
7. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Shore ND; Antonarakis ES; Cookson MS; Crawford ED; Morgans AK; Albala DM; Hafron J; Harris RG; Saltzstein D; Brown GA; Henderson J; Lowentritt B; Spier JM; Concepcion R
Prostate; 2020 May; 80(6):527-544. PubMed ID: 32130741
[TBL] [Abstract][Full Text] [Related]
9. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.
Ng CT; Bonilla HMG; Bryce AH; Singh P; Herrmann J
Curr Cardiol Rep; 2023 Aug; 25(8):889-899. PubMed ID: 37490155
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
